



OPEN FORUM MADRID

14 & 15 JUNE 2011

Speakers and Panelists

(in order of appearance)



Jose Martínez Olmos, Secretary General of the Ministry of Health, Social Policy and Equality of Spain

Jose Martínez Olmos (Guadix, Granada, Spain, 1958). Bachelor of medicine and surgery at the University of Granada. Specialized in Preventive Medicine and Public Health. Master of Public Health and Health Administration. Though his current position is Health General Secretary, his permanent position is professor at the Public Health School of Andalucía (EASP) since 1988, after having worked for the Directorate General for Primary Health Care and Health Promotion at the Andalucía Autonomic Government (1984-1988). At the EASP he has also performed tasks of coordinator of the Health Management and Health Policies Area as well as coordinator for ten years of the Master of Public Health and Health Management. He has directed more than fifty research studies in the fields of public health, disease prevention and health services management. He has also developed activities of health cooperation as an EASP expert in Argentina, Guatemala, Panama, Venezuela, Nicaragua and Bosnia-Herzegovina. Regarding his political dedication it is worth highlighting that during the period 2000-2004 he has been health advisor to the Socialist Parliament Group in the Congress of Deputies and to the Social and Migrant Policies Secretary within the executive led by Jose Luis Rodriguez Zapatero. He was appointed coordinator of the PSOE (Spanish Socialist Party) health electoral programme during last 2004 general elections that served as a basis for the current socialist Government programme in the field of health. Since April 2004 to September 2005 he has held the position of Director General of Pharmacy and Medical Devices of the Ministry of Health and Consumer Affairs. In this position he has been working in the start-up of relevant initiatives such as the Pharmaceutical Policy Strategic Plan and also in the development of the new Guarantees and Rational Use of Medicinal Products and Medical Devices Law. Since September 2005 up until now, Jose Martínez Olmos is the Health General Secretary of the Ministry of Health, Social Policy and Equality. In this ministerial responsibility it can be pointed out his work in the development of the Quality Plan for the National Health System with a very relevant focus on the close work with scientific societies, as well as (this is way he is now today) his work encouraging health technology assessment through the definition of the main lines of the NHS (National Health System) HTA (Health Technology Assessment) Plan developed together with the agencies and assessment units in our country and financed with Quality Plan funds, a project that is marking a milestone in the history of our system as far as health technology assessment concerns.



Dr. Ivan Eržen, State Secretary of the Ministry of Health of the Republic of Slovenia

Ivan Eržen was born on 23 June 1957 in Ljubljana. In 1982 he graduated from the Faculty of Medicine in Ljubljana. He earned his MSc in 1987 and successfully defended his PhD thesis in 2004.

He began his career as a doctor in the department of epidemiology at the University Institute of Health and Social Care in Ljubljana. After five years of work, he became head of the department for hygiene and epidemiology and assistant director at the Celje Institute of Public Health, where he was responsible for expert matters. In 1992 he took over the Celje Institute of Public Health, where he remained at the helm until he took office at the Ministry of Health.

Among his colleagues, he is known to have extensive knowledge of the health care system. He was educated abroad and in Slovenia; he is also a university lecturer. His professional and research work has so far been linked mainly to the study of the impact of environmental factors on human health. He worked as a teacher and was mentor to students and young professionals pursuing postgraduate studies at the Faculty of Medicine of the University of Ljubljana. In 2006, he became assistant professor of public health. The Medical Chamber of Slovenia appointed him as chief mentor in the field of public health, covering epidemiology, hygiene and social medicine.

He is actively engaged in a number of Slovenian and foreign societies and professional organisations. He is president of the Slovenian Biomedical Informatics Society, founder of the Association of Teachers of Public Health of Slovenia, founder and president of the Cancer Society of the Celje region, and vice-president of the preventive medicine section of the Slovenian Medical Association.



Martin Seychell, Deputy Director General, DG Sanco

A graduate in chemistry and pharmaceutical technology, Mr. Seychell specialized in Chemical analysis. He has held important positions on several government boards and commissions in Malta, including the Food Safety Commission and the Pesticides Board. Mr Seychell occupied the post of Head of Directorate at the Malta Standards Authority between 2001 and 2006. He has been responsible for the implementation of a number of EU directives in the areas of risk assessment, food safety, chemicals and cosmetic products legislation, and has actively participated in negotiations on major technical proposals such as the new chemicals legislation, REACH, and in screening processes in the areas of free movement of goods, environment and agriculture during the process leading to Malta's accession to the EU. He held the post of Director of Environment in Malta between 2006 and 2011. As Director, he was responsible for a broad range of functions arising from the Maltese Environment Protection Act. He was appointed Deputy Director General for Health and Consumers at the European Commission in March 2011.



Alojz Peterle, Member of European Parliament and President of MEPs Against Cancer

Mr. Peterle has been a member of the European Parliament since 2004. Previously Slovenia's Prime Minister, the first since the country's independence, he also held the position of Minister for Foreign Affairs twice. Mr Peterle has been an active promoter of cancer care, in particular as co-chair of the informal all-party forum, 'MEPs against Cancer'. Mr Peterle himself has promoted a healthy lifestyle for a number of years and, after his own experience of cancer, has invested great effort in raising awareness of cancer issues. In 2008 Mr Peterle was the Rapporteur on the Commission's White Paper entitled 'Together for Health: A Strategic Approach for the EU 2008-2013'. Moreover, as Rapporteur for European partnership: Action against cancer, Mr Peterle continues to fight against cancer and to raise political awareness of one of the biggest health challenges we are facing in Europe and indeed worldwide. He has received a number of prestigious awards, including the European Voice's 'European of the Year' in 2003, a gold medal from the Luxembourg foundation, 'Mérite Européen' in 2004, The Parliament Magazine's Award 2008 and the Bulgarian APOZ Award for his contribution in the fight against cancer in 2009.



Jose M. Martin-Moreno, MD, PhD, MPH, DrPH, Director of Programme Management, World Health Organisation

Jose M. Martin-Moreno is the current Director of Programme Management at the World Health Organization, Regional Office for Europe. A Professor of Medicine and Public Health, he has held many prestigious positions (including a term as Director General of Public Health & Chief Medical Officer of Spain) and has participated in numerous international cancer and noncommunicable diseases initiatives. Having published a comparative analysis on National Cancer Control Programmes and collaborated with the Slovenian Presidency of the EU on cancer control, he is particularly well-placed to support European efforts to put noncommunicable diseases at the forefront of European health policy.



Ingrid Kössler, European Economic and Social Committee

Ingrid Kössler holds a Bachelor of Arts degree and a Master of Business Administration from the University of Gothenburg, School of Economics and Commercial Law. Ingrid Kössler has been involved in the Breast Cancer Organization since 1988, when she was diagnosed with breast cancer. She was president of the Swedish Breast Cancer Association 2001-2010. In 2004, Ingrid became a Board Member of EUROPA DONNA and was president (2006-2008). Due to family and own experiences from other cancer diagnoses Ingrid has developed a broader interest and engagement in the combat of cancer. She served as a board member of the Swedish Cancer Society 2005-2009 and was expert in the Official Inquiry on a National Cancer Control Strategy, Sweden and is now involved in the implementation of the National Cancer Control Strategy in Sweden and a board member of European Cancer Patient Coalition. Ingrid Kössler is Member of the European Economic and Social Committee in Brussels since 2006. In 2009, she was rapporteur on the European Partnership for Action Against Cancer.



Michael Cohen, NAT Commission Acting Chair, Committee of the Regions

Michael Cohen is 54 years old, married and has two children. During his career he got a lot of experience in managerial and political positions, in Malta and in International Institutions. He is a member of the Labour Party in Malta and has been active both locally and internationally within the Socialist and Social Democrats. Michael Cohen has been and is still, the Mayor of Kalkara for 10 years, since the year 2000. He is the President of the Local Council's Association, representing all Local Councils in Malta and Gozo. He is representing the Maltese Local Councils in various committees, such as the Local Councils Reform, the Malta Environment and Planning Authority, member of the Board of the Urban improvement fund, Chairman of the LES Stakeholders Committee and member of the Task force on the Waste Strategy. Michael Cohen is the Head of the Maltese Delegation in the Congress of Local and Regional Authorities within the Council of Europe. He is also a full member of the Institutional Committee, monitoring the European Charter for Local self Government in the 47 European countries that have ratified the Charter. He is also the Head of the Maltese Delegation in the Committee of the Regions, which is the second largest political institution in the European Union. He is the Vice President of the COR Bureau and is officially representing the interest of Local and Regional Authorities of Malta. Michael Cohen has recently been appointed as the First Vice President and acting Chairman of the Commission for Natural Resources in the Committee of the Regions, which is responsible for, Maritime Affairs, Agriculture, Public Health, Consumer rights and Tourism. He is a full member of the Ad hoc committee for the future composition of the Committee of the Regions, defending Malta's number of seats in this institution. He is also full member in ARLEM, the Local and Regional Euro-Mediterranean Assembly, following up the Barcelona Process and the Union for the Mediterranean, promoting co-operation between Mediterranean partners.



Octavi Quintana Trias, Director of European Research Area

Octavi Quintana-Trias is currently the director of the European Research Area. He has a Master's Degree in Public Health (University of Columbia, USA, 1986), is a Specialist in Critical Care (University of Valencia, 1980) and a Medical Doctor (University of Barcelona, 1976). His previous positions include Director of Energy (EURATOM), DG RTD from 2008-2011, Director of Health Research, DG RTD from 2002-2007, Director of International Affairs of the Spanish Ministry of Health and Consumers from 2000-2002 and Deputy Director General of the INSALUD (organization responsible for the management of the health care system in Spain) (1990-2000). He is also a professor of several universities in Spain, Europe and the US on bioethics and quality assurance. He has authored a number of papers in Spanish and international journals and is also the author of a book on "Ethical dilemmas at the end of life".



Dr. Wendy Yared, Director, ECL

Dr Wendy Yared is Director of the Association of European Cancer Leagues (ECL), a pan-European alliance of national and regional cancer leagues created in 1980. ECL facilitates the collaboration among cancer leagues throughout Europe and influence EU and pan-European policies. Dr Yared works with the Board toward ECL's central purpose of identifying and promoting common strategies in cancer control, and toward achieving health equity in cancer prevention, treatment and services. Prior to joining ECL, Dr Yared's professional history includes managing the regional health policy programme at the World Health Organization, Regional Office for Europe in Copenhagen; conducting research on public health issues, ranging from tobacco control issues to breast cancer screening policies to public health and digital media; consulting for the European Parliament in Luxembourg; and managing projects for the United States Public Health Service. She also occasionally acts as a consultant on health systems and policy issues. Her academic degrees are from the USA and include a DrPH (Doctor of Public Health) in International Health Systems from the Johns Hopkins University, an MPH (Master of Public Health) in Health Policy from the University of California at Berkeley, and an undergraduate degree in psychology and biostatistics also from the University of California.



Ahti Anttila, Finnish Cancer Registry

Ahti Anttila is the Director of Research of the Mass Screening Registry of the Finnish Cancer Registry, Helsinki. He is also an adjunct professor in epidemiology at the School of Public Health, University of Tampere, Finland. His research activities involve occupational and environmental risk factors and prevention of cancer, and evaluation of cancer screening programmes. Dr Anttila is an editor of the EU Guidelines for Quality Assurance in Cervical Cancer Screening, developed in collaboration with the International Agency for Research on Cancer. He works as the package leader for 'Screening and Early Diagnosis' within the Partnership joint action.



Dr. Milena Sant, Istituto Nazionale Tumori, Milano

WP9 leader: Milena Sant, MD, neurologist, epidemiologist
From 1981 to 1986 clinical and research activity at the Italian Neurological Scientific Institute C Besta, Milano. She worked in the neuroepidemiology unit and participated in several national and international research projects. Since 1987 she works as Senior Epidemiologist at the Istituto Nazionale Tumori, Milano, Milan National Cancer Institute where, since 2005, she is director of the analytical epidemiology Unit. She is the Scientific co-ordinator of EUROCARE, a cancer registry based project on survival and care of European cancer patients, which started in 1989 and is now at its 5^o round. She is member of the EUROCARE Steering committee and of the data analysis group. She coauthored the main scientific publications in leading medical and public health journals produced by EUROCARE. She is principal investigator of the EUROCARE High Resolution clinical studies, aimed to interpret interregional and overtime cancer survival differences, by collecting detailed clinical information on patients samples. In 2000-2004 project leader of several research projects funded by the EU (Europe Against Cancer programme) on survival and care of breast cancer patients. Project leader of HAEMACARE, a EU (Public Health programme, DGSANCO) project on survival and care of haematological malignancies in Europe Project leader of several Italian studies on survival and care of cancer patients in Italy. Since 2011 project leader of WorkPackage 9 of the European Partnership Against Cancer Project (EPAAC), on epidemiological indicators on Cancer.



Dr. Tit Albreht, National Institute of Public Health, Slovenia

Tit Albreht, Dr. (1961), Slovenian, Medical Doctor, Doctorate of Science in Health Services Research (Erasmus University Rotterdam), Head of the Centre for Analyses of Health Systems, Institute of Public Health of the Republic of Slovenia, Researcher in the field of health services research, health policy and health systems research, member of the Scientific Committee of EUPHA, member of Academy Health, member of the Slovenian Preventive Medicine Society – currently also member of its Board, member of the Health Council of the Ministry of Health of Slovenia. He acts as a reviewer of several scientific journals and of projects submitted for financing to the European Commission. On 27 January 2011 he successfully completed his PhD studies by obtaining a PhD in Health Services Research with the University of Amsterdam.



Dr. Julio Celis, European CanCer Organisation

Professor and Director, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark

Julio E. Celis is Professor and Director of the Institute of Cancer Biology at the Danish Cancer Society and is generally recognized as one of the founding fathers of proteomics. Julio Celis' group in Aarhus introduced the use of protein identification techniques to map HeLa cell proteins and developed the first protein database in 1981. In the early 1980s, the group also laid out the foundations for proteomics by annotating the databases with information gathered from applications to problems in cell biology, in particular cell proliferation and transformation. Together with J. Vandekerckhove he later introduced the use of large scale protein identification using microsequencing. Celis' group in Copenhagen has pioneered the use of proteomics to the analysis of bladder and breast cancer and introduced the concept of discovery-driven translational cancer research. Julio Celis is currently Chairman, Policy Committee at the European Cancer Organisation (ECCO), President of the European Association for Cancer Research (EACR), member of the board of the Organisation of European Cancer Institutes (OECI) and Member of the FP7 Advisory Group of Health Research.



Dr. Fabien Calvo, Deputy Director General, National Cancer Institute France

Fabien Calvo, MD PhD, Deputy General Director of the National Cancer Institute, France, has been in charge of the Research Programmes since April 2007. Fabien CALVO is also the director of the Cancer Multi-Institutions Alliance (including INSERM, CNRS, Universities and University-hospitals) in France. Previously resident and senior registrar of Paris Hospitals, research associate of the National Cancer Institute in Bethesda (NIH / NCI / DCT, USA), he specialised in oncology and haematology. He is currently a professor of pharmacology at the Denis Diderot Medical University in Paris. He has been the director of the Saint-Louis Hospital CIC (clinical investigation center) and he was the director of INSERM unit 716 on the identification of new molecular targets for the treatment of cancer from 1995 to 2008. He is a member of the post-graduate school "oncogenesis fundamental basis". He also headed the clinical research programmes in cancer in the Paris area. He has published more than 200 original and review articles. He also worked as a coordinator of the cancer mission for the Director of the Research and Innovation department, Ministry of Research and Higher Education in 2006 and 2007. His spheres of activity and interest are the biology of metastatic processes, especially proteases, translational research, preclinical pharmacology and early clinical trials in haematology and oncology.

Dr. Rafael de Andres-Medina, Instituto de Salud Carlos III



Rafael de Andres-Medina is Chief of the Docs. and Technical Studies Department, at the Fund for Health Research (FIS) of the Institute of Health Carlos III (Madrid, Spain), since 2004. He has held various positions at his current institute, his previous national positions include Secretary General of the National Plan for AIDS of Spain (Ministry of Health and Consumers Welfare, Madrid), 1987-1990, HIV/AIDS Unit at the National Center for Microbiology, Immunology and Virology applied to Public Health Majadahonda (Spain), 1985-1987 and Virologist at the Research Center of the University Hospital "La Fe", Valencia (Spain), 1977-1985. He has also worked on several actions regarding ERANets: E-RARE (European Research Area on Rare Diseases), NEURON (Network of European funding for Neuroscience research), Transcan (ERA-NET on Translational Cancer Research), EuroNanoMed (EUROpean network of trans-national collaborative projects in the field of NANOMEDicine RTD), PRIOMEDCHILD and Eurocan+plus. He has also collaborated on actions regarding the European Strategic Forum for Research Infrastructures (ESFRIs): ECRIN (European Clinical Research Infrastructures Network and Biotherapy), EATRIS (European Advanced Translational Research Infrastructure), BBMRI (Biobanking and Biomolecular Resources Research Infrastructure) and ERINHA (European Research Infrastructure on Highly Pathogenic Agents).



Professor Richard Sullivan, Kings Health Partners Integrated Cancer Centre, Centre for Global OncoPolicy and Health

Richard is Director of External Affairs, Kings Health Partners Integrated Cancer Centre, & Director of the new Centre for Global OncoPolicy & Health with the European Institute of Oncology. Richard qualified in medicine at St. Marys Hospital, London. Following training in surgery he undertook a PhD and post-doctoral research in cell signalling at UCL. He then worked in a senior role in the pharmaceutical industry before spending 10 years with Cancer Research UK as clinical director.

Richard serves on a number of international advisory boards, e.g. Charite Comprehensive Cancer Centre Berlin, Irish Clinical Oncology Group, Marjan Centre for Conflict & Conservation, and is past UK Director of the Council for Emerging National Security Affairs (CENSA) a Washington-based national security think-tank. His current research programmes cover the social and political policy of cancer (OncoPolicy), including e-policy (**europcancercoms** project) and global public health challenges in transitional, high risk conflict areas focusing on DR Congo, Afghanistan & Libya.



Dr. Maria Ferrantini, TRANSCAN

Maria Ferrantini received her degree in Biology at the University of Rome "La Sapienza" in 1984 and began her scientific career at the Istituto Superiore di Sanità (ISS). Dr. Ferrantini's main research interests include: i) role of interferons in the control of viral infections and in the immune response against tumors; ii) cancer vaccines; iii) development of antitumor gene therapy; iv) biology of dendritic cells. In the recent years, she has been actively involved in the study and design of innovative antitumor immunotherapy strategies based on the use of dendritic cells. From 2006 to 2010 she has served as Head of the Section of Experimental Immunotherapy of the Dept. of Cell Biology and Neurosciences at ISS. Dr. Ferrantini is the ISS contact person in the ECRIN preparatory phase project and leader of the WP on GMP facilities for biotherapy. Since 1 January 2011, she has been appointed as Project Manager of the ERA-NET on Translational Cancer Research TRANSCAN by the Coordinator, the Italian Ministry of Health.



Dr. Simon Baconnier, Conticanet

Dr. Simon Baconnier was graduated, in biophysics at Grenoble University in 2003. He is the current Scientific manager of the Conticanet (CONnective TIssue CANcer NETwork) Network of excellence (FP6) (www.conticanet.com) and Head manager of the World Sarcoma Network (www.worldsarcomanetwork.com): Network of worldwide opinion leaders to promote and implement clinical research on very rare subtypes sarcoma.

Simon Baconnier is also the Chief Scientific Officer of OncoTherapy Science France, French affiliate of the Japanese bio-venture OncoTherapy Science Inc., involved in the development of innovative cancer treatments.



Dr. Ulrik Ringborg, EUROCAN Platform

Dr. Ringborg has been the Director of the Cancer Center Karolinska since 1994. He completed his doctoral thesis at the Karolinska Institute 1971 on Nucleolar RNA Synthesis, processing and transport in salivary gland cells of *Chironomus tentans*. He has been a member of the Research Board and the Governing Body of the Stockholm Cancer Society since 1992, a member of the Research Board and the Governing Body of the King Gustaf Vth Jubilee Fund since 1992, a member of the Research Board and the Governing Body (Vice Chairman 2004 -) of the Swedish Cancer Society, a member of the Steering Group of NOCI, EORTC since 2008, Chairman of the Advisory Board for UV-protection, Swedish Radiation Protection Authority since 2002. He has been Secretary General of the European Academy of Cancer Sciences since 2009 and co-ordinator of the EurocanPlatform project since 2010. He has contributed to over 280 publications in international journals and books, scientific focus on malignant melanoma.



Dr. Eugenio Santos, Cooperative Cancer Research Network

Dr Santos got his Ph.D. in 1978 and did postdoctoral work at the Roche Institute of Molecular Biology (Nutley, NJ) and the Laboratory of Cellular and Molecular Biology, National Cancer Institute, NIH (Bethesda, MD). Later on, he held PI positions at the NIH campus in the Laboratory of Molecular Microbiology, NIAID (85-90) and the Laboratory of Cellular and Molecular Biology, NCI (91-00). Since 2000 he is Professor at the Dept. of Microbiology & Genetics, and Director of the CIC Cancer Research Center sponsored by University of Salamanca (USAL) and the Spanish Research Council (CSIC). He is also national coordinator of the Cooperative Cancer Research Network (RTICC) sponsored by National Institute of Health Carlos III, Spain. After the isolation and characterization of the first human oncogene (*H-ras*), Dr. Santos' research has always focused on the structure, function and regulation of Ras oncogene family members.



Dr. Marina Pollan, Instituto de Salud Carlos III

Doctor in Medicine and Surgery at the Autonomous University of Madrid and Master of Public Health at the National School of Public Health in Madrid. She has worked in the field of cancer epidemiological research since 1990, at the National Centre of Epidemiology in the Carlos III Institute (CNE-ISCIII). During her first years at work, she enjoyed two scholarships that allowed her to stay and complete her formation in the Johns Hopkins School of Public Health in Baltimore (US) and to work for a short period in the Department of Occupational Health at the Karolinska Hospital in Stockholm (Sweden). She became head of the cancer epidemiology division inside the Cancer and Environmental Epidemiology unit in 2000. Dr Pollán has published more than 100 scientific papers in international journals and has lecture more than 100 conferences, seminars and presentations at conferences in national and international academic institutions. She has participated in several international and national advisory panels, mainly related with cancer surveillance and cancer risk factors. She has also been involved in the elaboration of regional and national strategies against cancer. Dr Pollán has been member of the evaluation boards coordinating the scientific reviewing process of projects in the following areas: 1) "Biomedicine" (2004-2005) and "Clinical Medicine and Epidemiological Research" (2006-2009) at the national agency for scientific evaluation (ANEP); 2) area of "Public Health" (2003-2004) at the national funding agency (FIS), 3) "Research of Excellence" at the Andalusian Agency (2010-2011). She is member of the Scientific Committee of her institute (ISCIII), the Ethics Committee of her institute (ISCIII) and the Scientific Committee of the Hospital Puerta de Hierro (Madrid). At international level, she has acted as evaluator of the European Commission in the Framework Programme VI, has participated in the peer-review process for different international journals. She chaired the international symposium of the European Society of Epidemiology in Toledo in 2003. She has participated in several Scientific Committees in different Workshops and Symposiums. Currently, she is member of the Scientific Council in the International Agency for Cancer Research (IARC). Dr Pollán's work has allowed her to establish collaborations with different groups and networks, including GEICAM, the Department of Human Genetic at CNIO, the Spanish network of cancer registries and the Spanish network of screening programs among others. Dr Pollán is member of the Spanish Society of Epidemiology (SEE) and had been in the board of the society during the period 2003-2006. She is also member of the board of the Spanish group for Breast Cancer Research (GEICAM). She is member of the Spanish Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP) and has been member of its steering committee (2007-2010).



Dr. Maria Masucci, INCA, Framework Programme 6

Maria G. Masucci is since 1997 professor of Virology at the Karolinska Institutet. She was born in Italy where she earned her medical degree in 1977 and specialization in Experimental Oncology in 1980 at the University of Ferrara. She obtained her PhD in Tumor Biology at Karolinska Institutet in 1985 under the supervision Georg and Eva Klein and became docent in Tumor immunology in 1987. Her research aims to understand how tumor viruses can stimulate cell growth and promote malignant transformation and how the immune defenses of the body deal with these abnormal cells. Her studies on viral subversion of the cellular environment are particularly focused on the ubiquitin proteasome system. She is a member of the Nobel Assembly at the Karolinska Institutet since 2002 and became a member of EMBO and of the Swedish Royal Academy of Science in 2006.



Prof T Kutluk, President of the Association of European Cancer Leagues (ECL)

Prof. Kutluk is the President of ECL and also the President of Turkish Association for Cancer Research and Control. In addition to his academic success with more than 100 publication in peer reviewed scientific journals and 350 citation in international medical Journals, he also has been involved in healthcare management in different positions for the last 14 years at Hacettepe University Hospitals in Ankara-Turkey which is one of the country's largest reference centers. He has been the CEO of Hacettepe University Hospitals since 2008 and has a long term experience on cancer prevention, advocacy, patient affairs, cancer communication and NGO management. He is also a board member of the Union for International Cancer Control (UICC).



Jean-Pierre Thierry, COCIR (European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry)

Jean-Pierre Thierry, MD MPH is a medical doctor from the Paris University and has obtained a master in economy of health and public health. He was invited by the National Library of Medicine to follow the NIH-NLM Fellowship Program of BioInformatics in 2006. He has been accepted as Allied Professional of ASCO and ESMO in 2009. He began his carrier as a researcher at INSERM. From 1983 to 1987 he was in charge of biomedical and health industry technology assessment at the CESTA. In the 90s, as an independent consultant, he worked for the French National Medical Board and the National Center for Hospital Equipement in France and for the EC DGXIII, as expert, on subjects related to Healthcare IT, Patient Safety, risk management, health economics, and ICT-supported health system re-engineering. Between 2002 and 2007, he held the position of CIO for two large hospitals in the Paris region. Jean-Pierre Thierry joined Agfa HealthCare in 2007 as Director Business Development Europe. He has been appointed as Chief Medical Officer of Agfa HealthCare (global) in July 2010.



Andras Fehervary, Novartis Oncology Europe

Andras Fehervary is Head of Market Access and External Affairs for Novartis Oncology Europe. Andras leads an integrated team of four directors responsible for Pricing & Health Economics; Reimbursement & Listing; Communications & PR; and Patient Advocacy and Professional Relations. Andras reports to Dr. Guido Guidi, President of Novartis Oncology Europe and is a member of the Strategy Committee Oncology Region Europe (SCORE). He is personally responsible for External Affairs for Novartis Oncology Europe Prior to joining Novartis, Andras was Head of European Policy & Public Affairs and of the Brussels government affairs office for Eli Lilly & Company. He held regional corporate affairs leadership positions for Central & Eastern Europe, Africa and the Middle East with Lilly. Previously he obtained more than ten years of related experience in other industries. He speaks native English, fluent Italian and Hungarian, as well as German and French. He holds MBA, DES, MALD, and BA degrees from INSEAD, IUHEI Geneva, the Fletcher School of Law & Diplomacy; the Johns Hopkins University, and the Nitze School of Advanced International Studies Bologna Center. Andras holds US and Hungarian citizenship and is currently based in Milan, Italy.

Dr. Jan-Willem van de Loo, DG Research and Innovation



Jan-Willem van de Loo obtained his Biology degree at the University of Utrecht in 1991, following a year at the University of Wisconsin-Madison Medical School Graduate Program. He worked as a junior scientist at the Central Laboratory of the Red Cross Blood Transfusion Service (CLB), Amsterdam and obtained his PhD at the University of Leuven in 1999. He has approximately 15 years of full-time research experience in various laboratories, mainly abroad (Europe, USA), in the following areas: molecular microbiology and genetics, biochemistry, cell biology, oncology, immunology and virology. He held three postdoctoral positions in cancer research, including a Marie-Curie postdoctoral fellowship at the European Institute of Oncology (IEO) Milan. Since 2003 he's a Scientific Officer at the European Commission in charge of cancer research and coordination of cancer policy-oriented activities.



Dr. Josep Borras, Spanish Cancer Strategy

JOSEP M. BORRAS is scientific coordinator of the Spanish Cancer Strategy and associate professor of public health in the University of Barcelona. He is also director of the Cancer Plan of the Department of Health in the Catalan Government. He received his MD from the Autonomous University of Barcelona in 1981 and his PhD in epidemiology in 1989. He has worked for the Department of Health in cancer control and technology assessment in cancer (1988-1996) and was director of the Catalan Institute of Oncology (1996-2006). His main research interests include the analysis of trends in cancer incidence and mortality and health services research in determinants of utilization of cancer prevention and care.

JUNE 15, Spotlight on Healthcare



Dr. Elke van Hoof, Belgian Cancer Centre

Prof. dr. Elke Van Hoof is the director of the Belgian Cancer Center. She is a clinical psychologist by training and has a vast amount of experience in counseling surviving cancer patients and its family. She teaches health and medical psychology at the Vrije Universiteit Brussel. Elke Van Hoof has numerous published articles in international peer reviewed journals on survivorship and neuropsychological issues survivors struggle with. As head of the Belgian Cancer Center, she is in charge of evaluating the Belgian Cancer policy including the Belgian Cancer Plan. Future action for a Belgian cancer plan are identified in the center. Furthermore, the Belgian Cancer Center acts as an integration center that centralizes existing knowledge and expertise on a national and international level. Subsequently, all stakeholders are included. The mission of the Belgian Cancer Center can be summarized as follows: facilitating, integrating and advising.



Jeni Bremner, European Health Management Association

Jeni Bremner, BA MSc RGN, British; Director of the European Health Management Association. She is a qualified nurse and also holds an M.Sc in Health Education from the University of London and an M.Sc in Health Economics from the University of York. She has substantial experience in the management and design of health and social care systems both working within health and social care systems and as a consultant. She has many years political and policy experience in the fields of public health, health care and social care. Prior to taking up post at EHMA she worked in the UK leading the national local government policy agenda across a number of areas including older peoples services, children services, education, health, public health, social care and criminal justice. She has been Director of EHMA since March 2007.



Anita Margulies, European Oncology Nursing Society

Anita Margulies undertook her nursing specialty at: clinical oncology nursing and nursing education at the University Hospital Zürich, and various schools of nursing in Switzerland. At present, she is now working free-lance in consulting and education. She is a board member of EONS, Swiss Oncology Nursing Society and Zürich Cancer League. She runs lectures, workshops and courses in collaboration with European Oncology Nursing Society, Swiss Oncology Nursing Society, Swiss Cancer League, University Hospital Zürich, Swiss pharmacists association and the Zürich College of Applied Sciences. She has participated in the following projects: Educational program development - Masters in advanced studies, National Cancer Program - Switzerland 2011-2015, Federal Certification: oncology nursing diploma (ongoing), Zürich, Cancer Society: new information and meeting center for patients, project oral therapy in Switzerland - supporting adherence and safety, Nurses in clinical trials SAKK/SIAK, protocol reviewing board. She has published articles in various oncology journals and is a co-editor of "Onkologische Krankenpflege", Springer Verlag, 5th ed. 2010 and "Medikamente in der Tumorthherapie" Springer Verlag 3.edition in progress.



Pascal Garel, European Hospital and Healthcare Federation

Pascal Garel is the Chief Executive of HOPE - Brussels (European Hospital and Healthcare Federation). He has actively participated in organising several seminars and congresses. He has coordinated the HOPE exchange programme in France from 1992-1999. He has also participated in a large number of European projects financed through a variety of European programmes (Comett, FORCE, BIOMED, BIOTECH, Léonardo, FP 6, Public Health). He was previously employed at the *Fédération Hospitalière de France* - Paris (2000-2003), at the *Centre hospitalier universitaire* - Rouen (France) (1996-2000), at the French Ministry of Social Affairs and Health at the central administration level of decision for the social and health sector (1994-1996) and the *Centre hospitalier Universitaire* - Nantes (France) (1989-1994). He has written several publications concerning the European and international field.



Dr. Jerzy Kowalczyk, European Society for Pediatric Oncology (SIOPE)

Jerzy R. Kowalczyk born on 1st March, 1948 in Poland. Graduated at Medical School of Lublin in 1972. In 1973 he was employed in the Institute of Paediatrics, Medical School, Lublin as assistant. Ph.D. degree obtained in 1979, and habilitation in 1983. In 1980/81 he worked at Roswell Park Cancer Inst., Buffalo, N.Y. as a Fogarty Research Fellow. After the completion of the Fellowship in USA he continued the research and medical training in the Institute of Paediatrics in Lublin. The title of Professor of Paediatrics received in 1989. He is a certified specialist in paediatrics, paediatric oncology and haematology, clinical transplantology. Since 1992 he is a Head, Department of Paediatric Haematology, Oncology and Transplantology, Children`s University Hospital, Lublin and a Chairman, II Department of Paediatrics, Medical University in Lublin. He has published over 250 papers in scientific journals and 3 monographs. He is currently a National Consultant in paediatric oncology and haematology at the Polish Ministry of Health, and a member of the Board of the International BFM Study Group. As a SIOP Europe Board Member since 2007 he is involved in activities to decrease inequalities in childhood cancer care in Europe.



Roswitha Britz, Spanish Breast Cancer Federation (FECMA)

Roswitha Britz, 61 years old, German origin, living in Spain for 33 years, Spanish spouse, 3 children and 3 grandchildren. In 1999 she was diagnosed with a breast cancer, and after pursuing medical treatment, Roswitha joined a group of women affected by the disease, thereafter starting up ALBA, the Association of Women with Breast Cancer in Menorca, Spain. From the very beginning, the Association contacts with other groups of women with the same affliction in Spain, and soon the Spanish Breast Cancer Federation, FECMA, is created. From foundation, Roswitha is the representative of her group in the Federation, and from 2004 is Member of the Board of FECMA.



Vladimir Stevanovic, Organisation for Economic Co-operation and Development (OECD)

Vladimir Stevanovic completed training in Paediatrics and Public Health. He also graduated with a Masters in medical informatics. He started working at the New Zealand Ministry of Health in 1996. He is Team Leader of Clinical Advisory and Principal Technical Specialist in the Health and Disability Intelligence Unit. He has been involved in many programs aimed at improving medical care and health outcomes. He also developed a clinical benchmarking system for secondary health care. Vladimir has been seconded to the OECD Health Division by the New Zealand Ministry of Health since 2009. He is working as Consultant in the Health Care Quality Indicators area.



Karen Benn, EUROPA DONNA

Policy Officer and Training Manager, EUROPA DONNA-The European Breast Cancer Coalition. Karen Benn joined ED, the head office of which is in Milan, in 2003 and is its Policy Officer. As such, she represents EUROPA DONNA at EU level to the European Parliament, the European Commission and other EU organisations and projects such as EPF (European Patients' Forum), EUROCAN, ECN and is a member of the TRANSBIG consortium's Spreading of Excellence Committee. Karen also runs all aspects of ED's annual Advocacy Training course and is in charge of membership for EUROPA DONNA; she is also ED's website manager; she researches and designs EUROPA DONNA surveys such as on Genetic Testing for Hereditary Breast Cancer; Tissue Banking and Metastatic Breast Cancer; she was also closely involved with the design of ED's National Rep Day and its annual Breast Health Day information campaign. Prior to joining EUROPA DONNA, Karen worked for Deutsche Bank in Milan, in charge of Strategic Partnerships for bank's "Maxblue" project. Before that she lived and worked in London for 13 years. She worked at PriceWaterhouseCoopers (previously Coopers & Lybrand) for most of that time, as a Business Analyst and latterly as a Business Development Manager. Karen was born and bred in Dublin, attending University College Dublin where she did a B.A. (Hons) in History and English Literature.



Dr. Luzia Travado, National Coordination for Oncological Diseases, Ministry of Health Portugal, International Psycho-oncology Centre

Clinical psychologist and psychotherapist specialized in health psychology and psycho-oncology. Chief of Clinical Psychology at Central Lisbon Hospital Centre-Hospital S. José, where she began her career and has pioneered psychosocial programs for chronic patients due to trauma or disease (including cancer) since 1985. She teaches psycho-oncology and communication skills and has published scientific papers in peer-review journals. Serves as adviser for the National Coordination for Oncological Diseases, Ministry of Health, Portugal since 2007, and was nominated by the Health Minister to represent Portugal in the EPAAC, leading the Psychosocial Oncology Action in Healthcare WP7 of JA. Member of International Psycho-Oncology Society.



Professor Stein Kaasa, European Association for Palliative Care

Stein Kaasa is Professor of Palliative Medicine at the Institute of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim (NTNU), Director of the European Palliative Care Research Centre (PRC), Director of the Cancer Department, St. Olavs Trondheim University Hospital and Cancer Director, Norwegian Directorate for Health. He also holds the position as chair of the European Association for Palliative Care Research Network (EAPC RN) and is a member of the Board of Directors of the International Association for Hospice & Palliative Care (IAHPC). Professor Kaasa is the leader of Work package (WP) 3 in “Reflecting the Positive diversities of European priorities for research and measurement in end of life care” (PRISMA); a 7th Framework EU funded project under the call “Optimising research on end of life care of cancer patients” 2008-2011. In addition, he is also the work package leader in two new 7th Framework EU funded projects: “Implementation of quality indicators in PAlliative Care sTudy” (IMPACT) and “European Intersectorial and Multi-disciplinary Palliative Care Research Training” (EURO IMPACT). From 2006 to 2010 he was the principal investigator and director of the EU 6th Framework funded collaborative “The European Palliative Care Research Collaborative (EPCRC)”. In 2009, he established the “The European Palliative Care Research Centre (PRC)” through an initiative by the palliative care research community and EAPC among others (www.ntnu.no/prc). The PRC is establishing formal collaboration with clinical and academic institutions and individual researchers across Europe and from other parts of the world. The PRC has also established an international PhD programme in palliative care. The EAPC RN will be an important contributor and facilitator of this work. Professor Kaasa’s main research interests are:

- Basic research in assessment and classification of symptoms and subjective health
- Intervention and prospective clinical studies in palliative medicine and cancer care
- Symptom treatment including translational research on opioids and on cachexia

Professor Kaasa has published more than 350 articles and book chapters. He has authored the Nordic Textbook of Palliative Care, is co-author of the Oxford Textbook of Palliative Medicine 4th edition and he is on the editorial board of Palliative Medicine. Professor Kaasa advises many international journals, either as an advisory board member or as a reviewer. He is also an expert reviewer in the EU’s 7th Frame Work.



Dr. Alessandro Laviano, European Society for Clinical Nutrition and Metabolism

Alessandro Laviano, MD, is associate professor of Internal Medicine at the Department of Clinical Medicine, Sapienza University of Rome, Italy. Dr. Laviano’s main research interest is cancer anorexia and cachexia. In particular, Dr. Laviano has been studying the integration of pharmacologic and nutritional approaches to cancer patients. Dr. Laviano is the current chairman of the Educational and Clinical Practice Committee of the European Society for Clinical Nutrition and Metabolism (ESPEN). Dr. Laviano is Associate Editor of *Clinical Nutrition*, *Journal of Cachexia, Sarcopenia and Muscle*, and *British Journal of Nutrition*. Dr. Laviano’s studies have been funded by private and public institutions.



Dr. Paolo Casali, European Society for Medical Oncology

Paolo G. Casali, MD, medical oncologist, is head of the Adult Mesenchymal Tumour Medical Oncology Unit, Istituto Nazionale Tumori, Milan, Italy. He also serves as Secretary of the Ethics Committee of this institution. His clinical and research activities focus on rare tumors, especially adult sarcomas, including gastrointestinal stromal tumors (GIST), and uncommon histological types. He is the Secretary of the Italian Sarcoma Group, a national cooperative group for clinical and translational research on soft tissue and bone sarcomas, and is a member of the EORTC Soft Tissue & Bone Sarcoma Group. He chairs the Italian Network on Rare Tumors, a collaborative effort among Italian cancer centers, which tries to exploit distant patient sharing in order to improve quality of care and diminish health migration for rare solid cancers. He acts as an Editor of START ("State-of-the-Art Oncology in Europe"), an Italian-based, European state-of-the-art instrument on cancer treatment. He is a member of the Executive Board of ESMO (European Society for Medical Oncology) as chair of the Public Policy/European Affairs Committee, and is Faculty Coordinator for Sarcoma. He is a member of the Policy Committee of ECCO (European Cancer Organization). He received his medical degree in 1984 in Milan, and trained at the Istituto Nazionale Tumori. He is certified in Clinical Oncology and Haematology, and has the ESMO Certificate in Medical Oncology. He teaches Medical Therapy of Rare Cancers at the Milan University postgraduate school in Oncology.